Comparative Pharmacology
Head-to-head clinical analysis: LUMATEPERONE TOSYLATE versus LURASIDONE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUMATEPERONE TOSYLATE versus LURASIDONE HYDROCHLORIDE.
LUMATEPERONE TOSYLATE vs LURASIDONE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lumateperone tosylate is an atypical antipsychotic with a unique mechanism of action involving antagonism of serotonin 5-HT2A receptors, partial agonism of serotonin 5-HT1A receptors, and antagonism of dopamine D2 receptors; it also modulates glutamate via phosphorylation of GluN2B subunits and inhibits serotonin reuptake.
Lurasidone is an atypical antipsychotic that acts as a full antagonist at D2 and 5-HT2A receptors, with high affinity for 5-HT7 and 5-HT1A receptors, moderate affinity for alpha2C and alpha2A adrenergic receptors, and no appreciable affinity for H1, M1, or alpha1 receptors.
42 mg orally once daily
40 mg orally once daily initially, titrated to 80 mg once daily; maximum 80 mg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 24-29 hours, allowing once-daily dosing. Steady-state reached in about 5 days.
Terminal elimination half-life is approximately 18 hours (range 14–24 hours), supporting once-daily dosing.
Approximately 60% excreted in urine as metabolites (unchanged drug negligible) and 30% in feces via biliary elimination.
Approximately 80% of total radioactivity recovered in feces (67% as metabolites, 9% as unchanged drug) and 19% in urine (mostly metabolites); less than 1% excreted as unchanged parent in urine.
Category C
Category A/B
Atypical Antipsychotic
Atypical Antipsychotic